Dakota Wealth Management Boosts Holdings in Astrazeneca Plc $AZN

Dakota Wealth Management lifted its holdings in Astrazeneca Plc (NYSE:AZN) by 115.3% in the fourth quarter, HoldingsChannel reports. The firm owned 10,449 shares of the company’s stock after buying an additional 5,595 shares during the quarter. Dakota Wealth Management’s holdings in Astrazeneca were worth $961,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in AZN. Bank of America Corp DE boosted its position in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after buying an additional 1,461,786 shares during the period. Fisher Asset Management LLC increased its position in shares of Astrazeneca by 2.3% during the third quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock worth $1,623,604,000 after acquiring an additional 466,745 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Astrazeneca by 9.4% during the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after acquiring an additional 582,183 shares during the period. Holocene Advisors LP raised its stake in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after acquiring an additional 1,807,565 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Astrazeneca by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock valued at $438,342,000 after acquiring an additional 660,569 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of “Moderate Buy,” which supports the stock’s upside but does not by itself explain today’s move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc (NYSE:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

Wall Street Analysts Forecast Growth

AZN has been the subject of several recent research reports. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. HSBC reiterated a “buy” rating and issued a $108.00 price target on shares of Astrazeneca in a research note on Wednesday, December 10th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Finally, Citigroup initiated coverage on shares of Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Stock Performance

AZN stock opened at $188.57 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The company has a market cap of $292.45 billion, a P/E ratio of 32.48, a price-to-earnings-growth ratio of 1.42 and a beta of 0.32. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71.

Astrazeneca Dividend Announcement

The business also recently announced a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were given a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is 66.26%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.